NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 1 of 37  
 
 
 
 
 
 
 
 
 
Clinical Investigational Plan  
 
 
Study Title : A Multicenter, Prospective, Treat and Resect  IDE Feasibility Study of the 
CellFX® System for the Treatment of Basal Cell Carcinoma  (BCC) Lesions  
 
 
 
Short Title: CellFX  Treat & Resect  BCC Feasibility Study  
 
 Protocol No: NP -TR-014 
Version 2.0 
29-APR-2021 
 
 
IDE Number: G210100   
NCT: 04918 381 
 
 
Study  Sponsor:  
 
Pulse Biosciences, Inc.  
3957 Point Eden Way  
Hayward, CA 94545  
 
 
This document is a confidential communication of Pulse Biosciences, Inc.  The recipient agrees that no unpublished information 
contained herein will be published or disclosed without prior written approval of Pulse Biosciences, Inc. except that this do cument 
may be disclosed to appropriate institutional review  boards, ethics committees or duly authorized representatives of the U.S. Food 
and Drug Administration or other responsible regulatory authorities under the condition that confidentiality is maintained.  
 
PROPRIETARY AND CONFIDENTIAL  
 
 
 
  

NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 2 of 37  
TABLE OF CONTENTS  
 
STUDY CONTACTS  ................................ ................................ ................................ ..............................  4 
1.0 INTRODUCTION AND BACKGROUND  ................................ ................................ ................  5 
1.1 Basal Cell Carcinoma Lesions  ................................ ................................ ...............................  5 
1.2 Current Care  ................................ ................................ ................................ ..........................  5 
1.3 Non-Surgical Approach  ................................ ................................ ................................ ..........  5 
1.4 Surgical Approach  ................................ ................................ ................................ ..................  7 
1.5 Alternative Approach  ................................ ................................ ................................ ..............  8 
1.6 Study Rationale  ................................ ................................ ................................ ......................  8 
2.0 STUDY DEVICE DESCRIPTION  ................................ ................................ ...........................  9 
2.1 Pulse Bioscience CellFX® System  ................................ ................................ .........................  9 
2.2 Proposed Indication for Use ................................ ................................ ................................ . 10 
3.0 PROTOCOL  ................................ ................................ ................................ .........................  10 
3.1 Study Objectives  ................................ ................................ ................................ ..................  10 
3.2 Study Design  ................................ ................................ ................................ ........................  11 
3.3 CellFX Procedure  ................................ ................................ ................................ .................  12 
3.4 Site Selection  ................................ ................................ ................................ .......................  12 
3.5 Number of Subjects  ................................ ................................ ................................ .............  13 
3.6 Clinical Study Duration  ................................ ................................ ................................ .........  13 
4.0 STUDY  PROCEDURES  ................................ ................................ ................................ ...... 13 
4.1 Screening  ................................ ................................ ................................ .............................  13 
4.2 Subject Selection  ................................ ................................ ................................ .................  13 
4.2.1  Inclusion Criteria  ................................ ................................ ................................ ..................  13 
4.2.2  Exclusion Criteria  ................................ ................................ ................................ .................  14 
4.3 Process for Obtaining Informed Consent  ................................ ................................ .............  14 
4.3.1  Process for Obtaining Informed Consent  ................................ ................................ .............  15 
4.3.2  Addition of New Information  ................................ ................................ ................................ . 15 
4.4 Schedule of Events and Evaluations  ................................ ................................ ...................  16 
4.5 Screening / Enrollment Procedures (Visit 1)  ................................ ................................ ........  17 
4.5.1  Activities prior to or on same day as study enrollment  ................................ ........................  17 
4.5.2  Definition of Enrollment  ................................ ................................ ................................ ........  17 
4.5.3  CellFX Treatment Procedure  ................................ ................................ ...............................  17 
4.6 3-Day Follow -up Visit (Visit 2)  ................................ ................................ ..............................  18 
4.7 7-Day Follow -up Visit (Visit 3)  ................................ ................................ ..............................  18 
4.8 14-Day Follow -up Visit (Visit 4)  ................................ ................................ ............................  18 
4.9 30-Day Follow -up Visit (Visit 5)  ................................ ................................ ............................  18 
4.10  60-Day Follow -up Visit (B CC Surgical Excision Day – Visit 6)  ................................ ............  18 
4.11  14-Day Post -Excision Follow -up Visit (Visit 7)  ................................ ................................ ..... 19 
4.12  30-Day Post -Excision Follow -up Visit (Visit 8)  ................................ ................................ ..... 19 
4.13  60-Day Post -Excision Follow -up Visit (Visit 9)  ................................ ................................ ..... 19 
4.14  Subject Withdrawal  ................................ ................................ ................................ ..............  19 
4.15  Discontinuation of CellFX Treatment Session  ................................ ................................ ..... 20 
4.16  Lost to Follo w-Up ................................ ................................ ................................ .................  20 
5.0 BENEFITS AND RISKS  ................................ ................................ ................................ ....... 20 
5.1 Benefits  ................................ ................................ ................................ ................................  20 
5.2 Risks  ................................ ................................ ................................ ................................ .... 21 
5.3 Mitigation of Risks  ................................ ................................ ................................ ................  21 
6.0 STATISTICAL CONSIDERATIONS  ................................ ................................ .....................  22 
6.1 General Approach  ................................ ................................ ................................ ................  22 
6.2 Analysis of the Primary Effectiveness Endpoint  ................................ ................................ .. 22 
6.3 Analysis of Secondary Endpoints  ................................ ................................ ........................  22 
6.3.1  Change in Lesion Size  ................................ ................................ ................................ .........  22 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 3 of 37  
6.3.2  Lesion Reduction Category ................................ ................................ ................................ .. 22 
6.3.3  Partial response of target (study) lesion as assessed by WHO  criteria  .............................  23 
6.3.4  SCAR -Q Appearance Scale (Subject)  ................................ ................................ .................  23 
6.3.5  Manchester Scar Scale (Investigator)  ................................ ................................ ..................  23 
6.3.6  Healing assessment questions (Investigator)  ................................ ................................ ...... 23 
6.4 Safety Endpoints  ................................ ................................ ................................ ..................  24 
6.4.1  Primary Safety Endpoint  ................................ ................................ ................................ ...... 24 
6.4.2  Investigator Local Skin Reaction Assessment  ................................ ................................ ..... 24 
6.4.3  Participant Assessment of Procedural Pain ................................ ................................ .........  24 
6.5 Sample Size Determination  ................................ ................................ ................................ . 25 
6.6 Populations for Analyses  ................................ ................................ ................................ ..... 25 
6.7 Sub-Group Analyses  ................................ ................................ ................................ ............  25 
6.8 Interim Analyses  ................................ ................................ ................................ ..................  25 
6.9 Missing Data  ................................ ................................ ................................ ........................  25 
6.10  Exploratory Analysis  ................................ ................................ ................................ ............  25 
7.0 CLINICAL PHOTOGRAPHY  ................................ ................................ ................................  26 
8.0 ADVERSE EVENTS  ................................ ................................ ................................ ............  26 
8.1 Adverse Event Definitions  ................................ ................................ ................................ .... 27 
8.1.1  Adverse Event (AE): ( ISO 14155:2011 3.2 )................................ ................................ .........  27 
8.1.2  Adverse Device Effect (ADE): ( ISO 14155:2011 3.1 ) ................................ ..........................  27 
8.1.3  Serious Adverse Event (SAE) (ISO 14155:2011 3.37)  ................................ ........................  27 
8.1.4  Serious Adverse Device Effect (SADE): (ISO 14155:2011 3.36)  ................................ ........  27 
8.1.5  Unanticipated Adverse Device Effect (UADE): (21CFR812.3)  ................................ ............  28 
8.2 Device Deficiencies ( ISO 14155:2011 3.15 ) ................................ ................................ ........  28 
8.2.1  Definitions  ................................ ................................ ................................ ............................  28 
8.3 Safety Reporting Requirements  ................................ ................................ ...........................  28 
9.0 STUDY MANAGEMENT (SPONSOR RESPONSIBILITIES)  ................................ ..............  29 
9.1 Sponsor Ethical and Regulatory  Considerations ................................ ................................ .. 29 
9.2 Selection of Clinical Sites ................................ ................................ ................................ ..... 29 
9.3 Site Training  ................................ ................................ ................................ .........................  29 
9.4 Investigator Training  ................................ ................................ ................................ ............  30 
9.5 Monitoring of Study Sites  ................................ ................................ ................................ ..... 30 
9.5.1  Monitoring Methods  ................................ ................................ ................................ .............  30 
9.5.2  Periodic Monitoring Visits (Onsite and Remote)  ................................ ................................ .. 30 
9.5.3  Site Close -out Visit  ................................ ................................ ................................ ...............  31 
9.6 Protocol Deviations  ................................ ................................ ................................ ..............  31 
9.7 Study Completion  ................................ ................................ ................................ .................  31 
9.8 Audits / Ins pections  ................................ ................................ ................................ ..............  31 
9.9 Publication Policies  ................................ ................................ ................................ ..............  32 
9.10  Data Management  ................................ ................................ ................................ ...............  32 
9.11  Case Report Forms /Transmission of Data  ................................ ................................ .........  32 
9.12  Data Retention  ................................ ................................ ................................ .....................  32 
10.0  INVESTIGATOR RESPONSIBILITIES  ................................ ................................ ................  33 
10.1  IRB Approval and Informed Consent  ................................ ................................ ...................  33 
10.2  Data Collection and Reporting  ................................ ................................ .............................  33 
10.3  Source Documents / Records Retention  ................................ ................................ .............  34 
10.4  Device Accountability  ................................ ................................ ................................ ...........  34 
11.0  REFERENCES  ................................ ................................ ................................ ....................  35 
12.0  APPENDICES  ................................ ................................ ................................ ......................  35 
12.1  Appendix A: Patient Informed Consent  ................................ ................................ ................  35 
12.2  Appendix B: Case Report Forms  ................................ ................................ .........................  35 
APPENDIX A: Patient Informed Consent  ................................ ................................ ........................  36 
APPENDIX B: Case Report Forms  ................................ ................................ ................................ .. 37 
 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 4 of 37  
STUDY CONTACTS  
 
 Name, Address and Contact  
Study Sponsor  Pulse Biosciences, Inc.  
3957 Point Eden Way  
Hayward, CA 94545  
  
Official Sponsor Correspondent  William A. Knape   
VP, Clinical, Regulatory, and Quality Affairs  
Pulse Biosciences, Inc.  
3957 Point Eden Way  
Hayward, CA 94545  
Phone: 919 .757.2033  
bknape@pulsebiosciences.com  
Central Institutional Review Board  Advarra Institutional Review Board  
6940 Columbia Gateway Drive, Suite 110  
Columbia, MD 21046 USA  
Phone: 410.884.2900  
Dermatopathology/Core Lab  
 Darius Mehregan, M.D.  
Aurora Diagnostics  
Pinkus Dermatopathology Laboratory  
1314 North Macomb St  
Monroe, Mi. 48162  
Phone: 800.746.5870    
 
Clinical Photography  
 Canfield Scientific, Inc.  
4 Wood Hollow Road  
Parsippany, NJ 07054  
 
  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 5 of 37  
1.0 INTRODUCTION AND BACKGROUND  
1.1 Basal Cell Carcinoma  Lesions  
Basal cell carcinoma (BCC) arises from the basal cell layer of the epidermis and is the most 
common cancer among Caucasians globally .1 The lesions usually occur on sun -exposed skin in 
adults, and locations are stratified by risk.  Medium - and high -risk locations are the head, neck, 
genitals, hands, feet, and pretibial while low risk areas are the trunk and extremities (aside from 
the ankles and other areas included in the medium - and high -risk locations).2 BCC lesions are 
rarely lif e threatening and the primary goal of treatment is complete removal of the tumor with 
maximum preservation of function and cosmesis.2  
 
1.2 Current Care  
The current care of BCC lesions include s topical s such as  imiquimod cream , radiotherapy , 
curettage and electrodesiccation , cryosurgery, photodynamic therapy , MOHs surgery  and 
surgical excision depending on multiple factors such as sub -type of the BCC , risk status, lesion 
size,  anatomic location , patient age, etc . The currently recommended treat ments of 
electrodessication and curettage , surgical excision /MOHs surgery  or other modalities are often  
dependent upon the technique of the health care professional for adequate results  and often  
leave scars and require down time for healing .3   
 
1.3 Non -Surgical Approach  
 
Topical Treatments  
Topical Imiquimod 5% Cream  
Topical 5% Imiquimod Cream is indicated for use on primary s uperficial BCC lesions. It require s 
doses 5 times per week for 6 weeks  and is applied by the patient . Imiquimod is a toll -like receptor 
(TLR) -7 agonist and is thought to exert its anti -tumor effect via modification of the immune 
response and stimulation of apoptosis in BCC cells.4 Intense local inflammatory reactions can 
occur with side effects including  itching,  pain and tenderness at the target site,  burning, 
erythema,  scabbing, excoriation/flaking, induration,  edema, ulceration and vesicles.5 The 
cosmetic outcome for topical imi quimod cream is superior to surgical excision  but inferior in cure 
rate. 5% Imiquimod cream may also be used as pretreatment to Mohs in order to decrease tumor 
size and furthermore reduce surgical defect size  or as an adjuvant therapy .6 
 
Topical 5-fluorouracil  
5-fluorouracil  is a pyrimidine analogue which induces apoptosis due to cytotoxic metabolite 
incorporation into DNA and RNA.7 This treatment modality is approved for use for superficial 
BCCs and involves topical application two times per day for a minimum of two weeks. This 
method has similar efficacy, safety , and cosmetic outcomes as imiquimod.2 The most common 
skin effects include erythema, pruritus, dermatitis, burning sensation and photosensitivity.7 
 
Oral Medications/Systemic Therapies  
Hedgehog Pathway Inhibitors  
Current FDA approved hedgehog pathway inhibitors , such as  vismodegib and sonidegib , are used 
for locally advanced BCCs  in which curative  radiotherapy and surgery are not feasible . 
Vismodegib  is FDA approved for treatment in  adults with metastatic BCC or locally advanced BCC 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 6 of 37  
that has recurred following surgery or who are not candidates  for surgery or radiotherapy . 
Drawback s for hedgehog pathway inhibitors are that resistance  can be developed in advanced 
BCCs and A Es were seen in almost all subjects in clinical trials  conducted . The most common  AEs 
seen included muscle spasms, alopecia, nausea, weight loss and fatigue .2 
 
Intralesional Interferon   
Intralesional injection of interferon alpha -2b can be effective in treating low risk BCC lesions but 
it does not offer much patient convenience as it requires injections 3 times a week for 3 weeks  
and can be expensive . Side effects include erythema and flu -like symptoms.1,8 
 
Physical  Destruction  
Radiotherapy  (RT)/Radiation Therapy  
Radiotherapy, along with surgical excision  and Mohs surgery  have the lowest failure rates among 
treatment options for BCC with overall 5-year cure rates ranging from 79% -100%.9 This 
treatment modality is often utilized f or lesions in areas that are difficult to resect , where patients  
are not goo d candidates for surgery  and is recommended for patients over the age of 60 . The 
length of the treatment regimens may vary, as t he total  dose  and dose per fraction of 
radiotherapy used differ. The main concerns with this therapy are acute toxicity to normal cells, 
late r adiation toxicity and long -term side -effects due to radiotherapy.  Most published studies 
have concluded  cosmetic outcomes to be satisfactory where evaluated. A visible scar is common 
based on the dose regimen. Other  cosmesis related effects include alopecia, pigmentation 
change, telangiectasia, fibrosis/scar, atrophy , contraction and epiphora; and rarely soft tissue 
necrosis, bone necrosis, cataracts , dry eye, conjunctival scarring,  and eyelid deformity in 
published studies.9 
 
Cryo surgery  
This treatment method involves the application of extreme cold to  the lesion area with liquid 
nitrogen. The direct cooling applied to the BCC lesion disrupt s the cel lular architecture, 
membrane integrity, and enzymatic activity . Malignant cells are particularly sensitive to cryo 
therapy due to their nature of high -water content, high metabolism and microcirculation .7 Once 
the growth freezes, it tends to fall off within days. Treatment results may vary with this 
procedure; past research has shown that pigmentary changes  such as hypopigmentation  are 
common, as well as erythema, edema, blistering , hypertrophic scarring, alopecia, tissue 
distortion and milia or pyogenic granuloma formation . 7 The cosmetic outcome is lower for 
cryotherapy compared to other treatment modalities. The pigmentary changes that arise due to 
treatment is shown to be dependent on the patient’s Fitz patrick Scale ranking.  
 
Laser s & Photodynamic Therapy  (PDT)  
Photodynamic thera py is a light emitting therapy where  low risk BCC  lesions are treated with 
combined use of visible light and a photosensitizing agent, commonly  5-aminolevulinic acid 
(ALA) , methyl aminolevulinate (MAL)  or porfimer sodium . The skin is pre -treated using a 
photosensitizing, prescription gel that reacts with the light source, either IPL  (Intense pulsed 
light)  or a 405 -420 nanometer blue light laser .10 Generally, this mode of trea tment will require 
several treatment visits, such as 4 sessions at 4 -week interval when using the 405 -420nm blue 
light laser .10 Debulking prior to PDT has shown to be more efficacious and has become standard 
practice with this treatment method.7  This meth od has greater cosmesis when compared to 
surgical excision , with effects seen includ ing ulcerations  but is reserved for superficial BCC lesions 
less than 1 -2mm thick due to insufficient penetration of the photosensitizer and light source . 7 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 7 of 37  
PDT has similar efficacy as cryo, imiquimod and 5 -FU but higher recurrence rates compared to 
imiquimod and higher patient pain reported compared to other modalities .1 
 
Treatment of BCC with lasers include treatments with l ong pulsed 1064nm NDYAG Laser s and 
595 pulsed dye laser s. Lasers work to treat BCCs by specifically targeting the vasculature that 
supplies the tumor to reduce tumor burden or eliminate the BCC.11 Multiple treatments are often 
required. P ost laser treatment a crust appears and tends to fal l off after a week. Treatments may 
lead to transient side -effects including infection, erythema, edema, crusting and discoloration. 
The pigmentary changes that arise post -treatment may be dependent on Fitzpatrick Scale 
ratings.  
 
Curettage and Electro desiccation (C&E)  
This treatment modality is a recommended treatment option for low -risk basal cell carcinomas 
in non -hair-bearing areas  that do not involve tissue past the subcutaneous layer . 1  
The electrocautery procedure uses a pencil -shaped met al instrument or needle to destroy or 
heat the growth via a high -frequency electric current that is applied within the lesion.  
Curettage involves scraping off the BCC lesion with a sharp knife or small, spoon -shaped tool  
down to a firm layer of normal epidermis .1 Curettage may be combined with electrocautery to 
prevent regrowth of the lesion and it can also be used in conjunction with liquid nitrogen to 
produce better results than just using liquid nitrogen alone.  
When t he two procedures are combined, first, a curette is used to scrape off undesirable cells 
down to the level of uninvolved tissue. This is then followed by electrosurgery to widen the 
region of cell destruction and removal, and to cauterize the wound in orde r to limit bleeding. The 
healing process for such procedures can take a few weeks or longer, depending on the size of 
the wound and other factors. A scab forms and will generally fall off in a few days. The procedure 
can cause post -inflammatory hyperpigmen tation in the treated area and although 
electrocauterization provides complete removal, there is no guarantee that another lesion will 
not develop nearby. Risk factors include reopening of wounds, scarring, temporary or permanent 
nerve damage (in regions w ith extensive nerves), subcutaneous bleeding and/or infections.  
 
1.4 Surgical Approach  
 
Standard Surgical Excision  
This treatment modality is the standard of care for off -face BCC lesions , as it is the most effective 
and efficient for eliminating the BCC Lesion . This therapeutic method will be utilized in this study 
60 days post -NPS treatment  (Visit 6). It involves a standard excision with 4 -mm clinical margins 
and post -operative margin assessment with  second intention healing, linear repair or skin graft.2 
This treatment modality often leaves a scar and some areas are difficult to excise rendering this 
method infeasible.  
Mohs Micrographic Surgery  (MMS)  
Mohs Micrographic Surgery with margin assessment  is also a standard of care and has the lowest 
5-year recurrence rate (1% and 6% of primary and recurrent BCC lesions, respectively). It allows 
intraoperative analysis of 100% of the excision margin. 1 
 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 8 of 37  
1.5 Alternative Approach  
CellFX ® System  
The CellFX Syste m is intended to be used for dermatological procedures in adult patients (greater 
than or equal to 22 years old) for the reduction, removal, and/or clearance of cellular -based 
benign lesions and low -risk basal cell carcinoma (BCC) , as an alternative to surgery and other 
more destructive methods for removing skin lesions. The CellFX System  utilizes localized delivery 
of a timed series of low energy, nanosecond electrical pulses that can trigger regulated cell death.  
The effect on tis sue takes place in a very shallow depth of skin directly below the sterile 
treatment tip. Histology of skin treated with CellFX has demonstrated selective effects on  cellular 
structures, including melanocytes, epidermal cells , and adnexal structures, inclu ding  sebaceous 
glands  and eccrine glands , with no apparent damage to the adjacent acellular dermis.  The device 
delivers less energy to tissue, and does not emit thermal energy like  laser, electro -surgery , or 
electro -cautery equipment.  
 
Prior Clinical Stud ies Summary  
Thirteen  (13) clinical studies have been or are currently being conducted using IRB approved non -
significant risk protocols and consent with  the Nano -Pulse Stimulation  (NPS) device . Two  
approved IDE pivotal stud ies are currently being conducted. A combined total of approximately 
3,600 NPS application  cycles  have been delivered to  about 700  adult Subjects. Anatomic 
locations where NPS has been used include the face,  trunk , neck,  arms, legs, hands, and feet. 
Discomfort in all protocols was managed with localized injected buffered Lidocaine , often with  
epinephrine . Side effects consisted of relatively minor reactions consistent with routine wound 
healing. No device or procedure complications and no seriou s related adverse events were  
reported.  Only minor expected adverse skin effects  were observed that are expected to resolv e. 
 
A Non -Significant Risk ( NSR) Acne Feasibility study (NP -AF-009) was conducted using the Nano -
Pulse Stimulation (NPS) device on bac k acne . The study  involved the treatment of  acne lesions in  
a 7cmx7cm area of the back with 49 cycles of energy delivered via the 10.0mm x 10.0mm 
treatment tip across  a range of energy settings. The entire treatment area healed as expected 
with some residu al hyperpigmentation, which is expected to resolve over time.  
 
An initial NSR BCC feasibility  study (NP -BC-005) demonstrated that the NPS Device  was successful 
in treating basal cell carcinoma lesions without safety concerns. A portion of 1 -2 biopsy 
confirmed BCC lesions were treated in the 48 Subjects enrolled. 48 NPS  treated areas were 
evaluated by a board certified dermatopathologist . The re was  no presence  of BCC  located within 
the NPS treated area  in all samples analyzed  for superficial and nodular low risk BCC lesions . The 
treated area s showed favorable healing  clinically . 
 
 
1.6 Study Rationale   
The rationale for this treat -and-resect BCC  IDE feasibility study is to collect data on the  safety 
and effectiveness of the CellFX System  for the treatment of  low-risk BCC lesions in  adult subjects . 
The data derived from this feasibility study will additionally be utilized to  determine  an optimal 
treatment  for basal cell carcinoma and  design a pivotal study to support FDA approval for such 
intended use.  
  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 9 of 37  
2.0 STUDY DEVICE DESCRIPTION  
The study device being evaluated is the Pulse Bioscience CellFX® System . 
 
2.1 Pulse Bioscience  CellFX® System  
The CellFX  System  is manufactured by Pulse Biosciences, Inc. and  consists of an electrical pulse 
console (similar to  devices used to electro -coagulate tissue) combined with a handpiece  which is 
held by the clinician during application of pulses to  the skin surface. The handpiece  is coupled to 
a sterile, single patient -use treatment tip.  
Once the electrical pulse console is turned on and a  predetermined  treatment energy  setting is 
selected, a sequence of pre -programmed electrical pulses is administ ered to an area of skin 
directly beneath the treatment tip.  A common commercially available sterile contact  gel may be  
applied to the skin or treatment tip surface to ensure good electrical contact to the tissue. The 
three system components are as follows , shown in Figure s 1-3.  
1. CellFX  Console including a built -in touch screen for setting selection . 
2. CellFX Handpiece  (re-usable)  
3. Sterile Single Patient -Use CellFX Tip (multiple different tip sizes available)  
 
Figure 1 : CellFX Console  
 
Touchscreen Display
Accessories Drawer
Standby Indicator
Handpiece Connector
Locking Casters
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 10 of 37  
            
                        
 
 Figure 2 : CellFX Handpiece  
 
 
 
         Figure 3 : CellFX Tip s 
 
2.2 Proposed Indication for Use  
The Pulse Bioscience s’ CellFX System is investigational in the U.S. and the system is indicated for 
dermatologic procedures requiring ablation and resurfacing of the skin including the treatment  
of benign  and non -malignant lesions . 
 
 
3.0 PROTOCOL  
3.1 Study Objectives  
The primary objective s of this study are to evaluate the safety and effectiveness of the CellFX 
System in adults with low -risk basal cell carcinoma. Table 1 below reflects the study endpoints 
associated with the two objectives.  
 
 
 
 
 
 
 
 
 
 
 
LED Indic ator
Side Button –
Treatmen t Level 
Selection
10 Ft. CableTip R ecep tacle
Hook – For Hanging Handpiece
Finger Switch – Cycle Start
Console Connect or
7.5mm x 7.5mm Tips  10.0 mm x 10.0 mm 
Tips 5.0mm x 5.0mm Tips  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 11 of 37  
Table 1. Study Objectives and Endpoints  
 
Objectives  Endpoints  
Safety  
To evaluate the safety of the 
CellFX System in adults with 
low-risk basal cell carcinoma  Primary:  
• No serious  adverse events related to CellFX Treatment or Procedure  
Secondary:  
• Local Skin Reactions  (Investigator)  
• Procedural pain assessment (Subject)  
Effectiveness  
To evaluate the effectiveness of 
the CellFX System in adults with 
low-risk basal cell carcinoma  Primary:   
• Complete histological clearance of the target lesion on microscopic 
evaluation of hematoxylin and eosin stains  
Secondary:   
• Visible/clinical clearance of the target lesion by 
clinical/dermatoscopic evaluation  
• Partial response  of the study lesion as assessed by WHO  criteria  
(≥ 50% decrease in the product of the longest perpendicular  
diameter s of each  target lesion ) 
• SCAR -Q Appearance Scale (Subject)  
• Manchester Scar Scale (Investigator)  
• Healing assessment questions (Investigator)  
 
 
3.2 Study Design  
This study is designed as a  prospective , multicenter  IDE feasibility study  in up to 30  adult 
participants with low -risk basal cell carcinoma utilizing the  CellFX System  at up to 6 sites within 
the United States . The study will consist of a single treatment session with the CellFX System 
followed by surgical tumo r excision (with 5  mm margins) 60 days post -treatment.   
Eligible subjects with 1-2 histologically  confirmed , primary  BCC lesion (s) who meet  the inclusion 
and exclusion criteria will be enrolled. The BCC lesion (s) may be present anywhere on the body 
except  neck, axilla, hands, feet, or genitals . In cases where the subject has more than 1-2 BCC 
lesions that meet the study criteria, the PI will select the lesion(s) to include in the study.  
The subject will receive treatment of their confirmed BCC lesion (s) with the CellFX system. The 
treatment area will be evaluated at 3 -days, 7 -days, 14 -days , 30-days and 60 -days  post -NPS 
treatment. At the 60-day follow -up visit , participants will undergo complete surgical excision of 
the tumor plus 5  mm margins. The subject will return for 3 more follow -up visits post -excision at 
14 days (suture removal) , 30 days  and 60 days  (typical skin check post -surgical excision) for a 
total of 9 study visits.  The 3 -day, 7 -day,  and 30 -day post -NPS treatment follow -up visits as well 
as the 30 -day post -surgical excision visit may be performed as telemedicine visits.  
The excised tissue at the 60-day post -treatment visit will be shipped for histological analysis.  
Preparation and a nalysis of the excised tissue will be performed by Pinkus Dermatopathology 
Laboratory and a board certified dermatopathologist who has extensive experience in 
interpreting cutaneous neoplasms.  Details of the preparation, shipment and analysis of the 
excised tissue are provided in the Tissue Handling  and Analysis  Procedure.  
Photography of the study lesion(s) will be captured along with the investigator ’s assessme nts at 
all in-office visits. Detailed instructions for photography of the lesion area are provided in the 
photography instruction manual.  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 12 of 37  
 
3.3 CellFX Procedure  
The intended CellFX treatment device is described as the CellFX ® System using the skin contacting 
component referred to as the “tip” . The three available tip  sizes  for this study are the 5.0mm x 
5.0mm, 7.5mm x 7.5mm, and 10. 0mm x 10.0mm  tips defined in  length and width , which  may 
range from 2.0mm to 3.0mm in depth. When a treatment tip is attached, the CellFX Handpiece 
delivers a timed series of energy pulses , referred to as a “Cycle”. The subject will be treated with 
appropriate tip size s according to the  size of the  BCC lesion .  The tip depth will be selected 
according to  the guidelines defined in  Table 2a  below. The BCC lesion(s) will be  treated with a 
pre-determined  treatment energy level  per tip size within the range  provided  in Table 2b.   
Table 2 a: Treatment Tip Depth Selection Guidance  
Tip Depth  
(mm)  Criteria   
2.0 Standard r ecommended treatment depth tip  
 
3.0 Lesions with BCC located in the deeper dermis in the diagnostic biopsy sample.  
 
Diagnosed nodular/non -superficial BCC lesion located on the back or shoulder 
where skin is thicker and where the 2mm depth tip may not be sufficient.  
 
Table 2 b: Treatment Level Range per Tip  
Tip 
Size 
(L x W, mm)  Minimum  
Treatment Level 
per Cycle  
 (mJ/mm3)  Max imum  
Treatment Level 
per Cycle  
(mJ/mm3) 
5.0 x 5.0  45 155 
7.5 x 7.5 40 85 
10.0 x 10.0 20 85 
 
For this device, the term treatment level  (TL) refers to the energy density value (mJ/mm3) 
delivered to the tissue by the treatment tip per cycle.  These  treatment  levels  do not exceed the 
maximum safe ranges of settings previously tested in clinical studies . Multiple cycles of energy 
may be delivered with one or more tip sizes  in order to treat the entire BCC lesion (s) along with 
a defined 5 mm margin  during  a single Cell FX treatment session.  
 
A tattoo will be applied prior to the CellFX  treatment to identify the treatment area  for 
evaluation . Four  tattoo marks  will be placed to identify  the margin of the treatment zone within 
the tissue area of the eventual ellipse of the excision.  The tattoo may be “touched up” or re -
applied at future visits as needed.  The tattoo will be applied to the area of the skin designated 
to be removed during th e surgical excision of the BCC lesion on Day 60 (Visit 6). An analgesic will 
be used to manage potential treatment discomfort during the CellFX treatment.  
                                                 
3.4 Site Selection  
The study will be conducted at up to  6 clinical research sites. The sites will be selected based on 
the appropriate patient population, board certified dermatologist , and sufficient resources to 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 13 of 37  
support this IDE study.  
 
3.5 Number of Subjects  
Up to 30 subjects at up to 6 sites will be enrolled.  
 
3.6 Clinical Study Duration  
It is anticipated that the enrollment of subjects in this study will take approximately 2-3 months 
in duration. All subjects included in this IDE feasibility study will return for follow -up visits at 3-
days , 7-days, 1 4-days, 30-days , and 60-days  post -NPS treatment. At the 60-day follow -up visit, 
participants will undergo complete surgical excision of the tumor plus 5  mm margins. The subject 
will return for 3 more follow -up visits at 14 -days, 30-days , and 60 -days  post -excision for a total 
of 9 study  visits. The total study dur ation will be 7 months.    
 
4.0 STUDY PROCEDURES  
4.1 Screening  
Recruitment will be conducted via direct communication by the investigator and/or his/her 
designated staff , advertisement and/or office ads . The Informed Consent discussion and 
signature process will be conducted by the investigator and/or designated staff. No study -
specific assessments will be performed prior to obtaining consent.  
 
A Screen Failure will be defined as a subject who did not meet one or more of the following 
criteria:  
• Did not meet all inclusion and/or exclusion criteria  
• Did not sign informed consent  
• Signed the informed consent but d id not subsequently undergo a treatment with the 
CellFX syste m 
 
A screen failure will not be ass igned a subject ID and information on this subject will not be 
entered in the electronic database. Information will be transcribed on the enrollment/screen  
failure log.    
 
4.2 Subject Selection  
The study population includes Adults with low -risk basal cell carc inoma.  
 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known 
as protocol waivers or exemptions, is not permitted.  
4.2.1 Inclusion Criteria  
Candidates for this study must meet ALL the following criteria:  
1. Subject is at least 2 2 and no older than 8 5 years of  age. 
2. Subject has 1-2 primary, non -recurrent, superficial, or nodular visible basal cell 
carcinoma  lesion  up to  1.5 cm in size with well -defined borders that has been 
verified by biopsy.  
3. Lesion (s) is appropriate for full linear excision with 5  mm margins.  
4. Subject is capable of giving signed informed consent , which includes compliance 
with the requirements and restrictions listed in the ICF and in this protocol.  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 14 of 37  
5. Subject gives  volun tary,  written  informed  consent  to participate  in this clinical 
investigation and from whom consent has been  obtained.  
6. Subject is willing to have BCC lesion (s) treated in a single treatment session  and must 
comply with all study procedures including follow -up visits.  
7. Subject consent s to have photographs taken of the BCC lesion(s) . 
8. Subject agrees to refrain from using all other lesion removal products or treatments 
(topical medication including over -the-counter medications  or treatments from PI or 
another physician ) during the study period.  
9. Subject agrees to refrain from prolonged sun exposure of the treatment area during 
the study period.  
 
4.2.2 Exclusion Criteria  
Candidates will be excluded from the study if ANY of the following apply:  
1. Subject has an implantable electronic medical device  (i.e., pacemaker, implantable 
cardioverter defibrillator) . 
2. Subject has an active infection or history of infection in designated test area within 
four weeks  prior to treatment.  
3. Subject is not willing or able to sign the Informed Consent.  
4. Subject is known to be immune compromised /has a history of immunosuppression 
(e.g., organ transplant, long -term use of psoralen) or genetic disease  (e.g., nevoid 
basal cell carcinoma syndrome [Gorlin syndrome], xeroderma pigmentosum) . 
5. The basal cell carcinoma lesion intended for treatment with the CellFX System is on 
the face, neck, scalp, axilla, hands, feet, or genitals.  
6. The basal cell carcinoma intended for treatment with the CellFX System  is a high -risk 
BCC subtype including perineurial, infiltrative, sclerosing , morpheaform , 
desmoplastic , micronodular, basosquamous  or exhibiting aggressive growth 
patterns.  
7. Subject is known t o be a keloid producer.  
8. Subject has allergies to Lidocaine or Lidocaine -like products.  
9. Subject has a history of radiation to the area intended for treatment . 
10. Subject has  current or prior metastatic BCC . 
11. Subject is  currently being treated or has been previously treated with Sonidegib or 
Vismodegib . 
12. Subject has r ecurrent BCC lesions .  
13. Subject has a  systemic infection . 
14. Subject has a  history of epilepsy .  
15. Subject has a  history of cardiac arrhythmia, myocardial infarction or structural heart 
disease .  
16. Subject is employed by the sponsor, clinic site, or entity associated with the conduct 
of the study.  
17. Subject has  any condition or situation which, in the Investigator’s opi nion, puts the 
subject at significant risk, could confound the study results, or may interfere 
significantly with the subject’s participation in the study.  
18. Subject has  a history of u se of any other investigational drug, therapy, or device 
within the past 30 days of enrollment or concurrent participation in another research 
study , with the exception of participation in a COVID vaccination related clinical trial . 
 
4.3 Process for Obtaining Informed Consent  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 15 of 37  
Prior to undergoing any study -specific tests or procedures, the subject must sign and date the 
site’s current and approved Institutional Review Board (IRB) informed consent from to be eligible 
for study participation. The informed consent must contain all elements required by 21 CFR Part 
50 and ISO 1415 5:2011/AC:2011 and comply with the ethical principles of the Declaration of 
Helsinki.  
 
4.3.1  Process for Obtaining Informed Consent  
The patients will be informed by the Investigator or Investigator’s designee that they are 
free to refuse participation in this r esearch study. If they elect to participate, it will be 
made clear that they may withdraw from the study at any time without prejudicing 
further care.  
 
The Investigator or the Investigator’s designee will inform patients that their medical 
records will be subject to review by the sponsor or appropriate regulatory bodies. This 
information will be used during the analysis of the results of the clinical study, but the 
patients’ identities will be treated as confidential. Patients will be assigned a unique 
study subject code that will not reveal the patients’ identity, and this code will be used 
on all data and data collection forms during the study period.  The Investigator will 
explain the conditions of the study, giving the patient sufficient time to ask qu estions 
and to consider whether to participate. Eligible patients who agree to participate will be 
asked to sign and date an IRB approved informed consent. If the patient agrees, an IRB 
approved consent form will be provided to the patient for signature an d date. One copy 
shall be returned to the Investigator and filed in the patient’s case history; the other copy 
is for the patient to keep.  
 
4.3.2 Addition of New Information  
Pulse Biosciences, Inc. will revise the written informed consent form whenever new 
infor mation becomes available that may be relevant to the subject’s confirmed 
participation in the study. The revised information will be sent to the Investigator for 
approval by the IRB. After approval of the IRB, a copy of this information must be 
provided to  the participating subjects, and the informed consent process as described 
above needs to the repeated. Please follow the central IRB guidelines on the process of 
re-consenting subjects.  
  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 16 of 37  
4.4 Schedule of Events and Evaluations  
Schedule of events and evaluations required for this stu dy are provided in  Table 3. 
 
Table 3. Schedule of Events  
Study Activity/  
Procedure  Visit 1  
Screening/  
Enrollment  
& Tx  Visits 2 -4 
3, 7, 14 -days  
Post -Tx  Visits 5  
30-days  
Post -Tx Visit 6  
Excision  
(60-days 
Post -Tx) Visit 7  
14-days 
Post  
Excision  Visit 8  
30-days 
Post  
Excision  Visit 9  
60-days 
Post  
Excision  
Study Day  0 3/7/14  30 60 74 90 120 
Visit Window  Day 0  ±2 days  ±5 days  ±5 days  ±3 days  ±5 days  ±5 days  
Type of Visit  
OV – In-Office  Visit Required  
OV/TM  – In-Office Visit or      
                 Telemedicine Visit   OV Visit 2 &  3: 
OV/TM  
 
Visit 4: OV OV/TM  OV OV OV/TM  OV 
Inclusion/Exclusion   
Informed Consent            
Demographics, Medical HX, 
Fitzpatrick Skin Type , etc.           
Lesion History            
History of Pigmentary 
Changes            
Photographs     a    *    *    a    a    *     
Lesion Assessment 
(Investigator)     a    *    *    a        *     
Tattoo Treatment Area           
CellFX Treatment            
Procedural Pain Assessment 
(Subject )              
Surgical Excision            
Suture Removal  (as 
applicable)            
SCAR -Q Appearance Scale 
(Subject )       b       
Manchester Scar Scale 
(Investigator)        b       
Healing Assessment 
Questions (Investigator)        b       
Lesion Measurement           b    
Clinical Clearance 
Assessment        b    
Adverse Events                              
Study Exit            
a Pre- and post -procedure / Surgical Excision  / Suture Removal  
b Pre-procedure / Surgical Excision   
* Required for in -office visits only  
  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 17 of 37  
4.5 Screening / Enrollment  Procedures  (Visit 1)  
The following activities  are required at the time of the subject screening/ enrollment  visit.  The 
order of the activities may vary within reason as long as all activities are performed after 
consent is obtained.  The Screening Visit and  Treatment Visit (subject enrollment visit) may 
occur on different days.  
4.5.1 Activities prior to or on same day as stu dy enrollment  
• Evaluation for Inclusion/Exclusion criteria.  
• Collect Demographic information and medical history including but not limited to 
age,  gender , race, ethnicity, dermatologic conditions, and  Fitzpatrick skin type.                      
• Sign the cons ent form prior to any study activities.   
• Receive a copy of the signed consent form.  
 
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria.  Procedures conducted as part of the participant’s 
routine clinical management and obtained before signing of the ICF may be utilized for 
screening or baseline purposes provided the procedures met the protocol -specified 
criteria . 
4.5.2 Definition of Enrollment  
Once the subject has been consented  and has received a CellFX  treatment, the subject 
will be considered enrolled and each enrolled subject will be assigned a unique Study 
Identification Number.   
4.5.3 CellFX Treatment Procedure  
• 1-2 clinically diagnosed BCC lesion (s) that meet the study criteria will be selected by 
the treating investigator . The identified lesion (s) will be labeled.  
• Baseline photographs  will be taken  (prior to use of analgesic for pain  management  
and prior to tattooing ). 
• Baseline c linical measurements of the BCC lesion(s) shall be taken  
• The site investigator  will perform a baseline lesion(s) assessment.   
• A template will be applied to the skin and used to map out the treatment application.  
• A tattoo (4 marks ) will be applied within the area d esignated for excision to mark the 
treatment zones for the purpose of identifying the treatment area during evaluation.  
• An analgesic for pain manag ement , such as local injection of lidocaine,  will be 
administered  to the selected study lesion  area(s) .  
• Each  study  lesion will be treated  with the CellFX system  per Table 2 according to the 
treatment tips utilized.  
• The total number of treatment cycles with the CellFX system will be recorded.   
• The subject will be asked to rate his/her pain immediat ely after  the treatment 
session  for each lesion treated with  the CellFX system by using a numerical rating 
score , depicted in Figure 4 . 
• Post -procedure lesion assessment will be performed by the investigator . 
• Post -procedure p hotographic images of each selected lesion will be taken.  
• A light bandage and/or any physician  recommended dressing may be applied  before 
the subject leaves.  
• Any adverse events will be identified and documented.  
 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 18 of 37  
4.6 3-Day Follow -up Visit (Visit 2)  
• This visit may be performed  in-office or as a telemedicine  visit. 
• Photographic images of each study lesion will be taken. Photographs are not required  if the 
visit is not performed in -office.  
• All lesions will be  examined and  clinically assessed by the site investigator. If the visit is not 
performed in -office, clinical assessment is not required.  
• A light bandage and/or any physician recommended dressing may be applied post -
evaluation . 
• Any adverse events will be identified and documented. If the visit is not performed in office, 
the clinical site must inquire regarding any adverse events either by phone call, text, e -mail 
or video conference.  
 
4.7 7-Day Follow -up Visit (Visit 3)  
• This visit may be performed  in-office or  as a telemedicine  visit. 
• Photographic images of each study lesion will be taken. Photographs are not required  if the 
visit is not performed in -office.  
• All lesions will be  examined and  clinically assessed by the site investigator. If the visit is not 
performed in -office, clinical assessment is not required.  
• A light bandage and/or any physician recommended dressing may be applied post -
evaluation.  
• Any adverse events will be identified and documented. If the visit is not performed in office, 
the clinical site must inquire regarding a ny adverse events either by phone call, text, e -mail 
or video conference . 
 
4.8 14-Day Follow -up Visit (Visit 4)  
• Photographic images of each  study lesion will be taken.  
• All lesions will be clinically assessed by the investigator.  
• A light bandage and/or any ph ysician recommended dressing may be applied post -
evaluation.  
• Any adverse events will be identified and documented.  
 
4.9 30-Day Follow -up Visit (Visit 5)  
• This visit may be performed  in-office or  as a telemedicine  visit. 
• Photographic images of each study lesion will be taken. Photographs are not required  if 
the visit is not performed in -office.  
• All lesions will be  examined and  clinically assessed by the site investigator. If the visit is not 
performed in -office, clinical assessment is not required.  
• Any adverse events will be identified and documented. If the visit is not performed in 
office, the clinical site must inquire regarding any adverse events either by phone call, text, 
e-mail or video conference.  
 
4.10 60-Day Follow -up Visit ( BCC Surgical  Excision Day – Visit 6)  
• Photographic images of each study lesion will be taken.  
• All lesions will be clinically assessed by the investigator.  
• The site investigator shall assess each  treatment area based on the Manchester Sca r Scale 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 19 of 37  
prior to excision.  
• The site investigator shall complete the healing assessment questions  for each treatment 
area  prior to excision . 
• Clinical measurements of the BCC lesion(s) shall be taken  
• The site investigator shall complete the  clinical lesion clearance assessment for each 
treatment area prior to excision.  
• The subject shall assess each treatment area based on the SCAR -Q Appearance Scale prior 
to excision.  
• A complete surgical tumor excision will be performed by the investigator w ith at least 5mm 
margins for each study lesion.  
• The subject will be asked to rate his/her pain immediately after surgical excision by using a 
numerical rating score.  
• All tissue shall be handled and shipped to the dermatopathology laboratory per the Tissue 
Handling  and Analysis  Procedure.  
• Any adverse events will be identified and documented.  
 
4.11 14-Day Post -Excision  Follow -up Visit (Visit 7) 
• Photographic images of each study area will be taken . 
• Each  study area  will be clinically assessed by the investigator.  
• Sutures shall be removed , as applicable . 
• Photographic images of each study area will be taken post -suture removal.  
• Any adverse events will be identified and documented.  
 
4.12 30-Day Post -Excision Follow -up Vis it (Visit 8) 
• This visit may be performed in -office or may be performed as a  telemedicine  visit.  
• Photographic images of each study area  will be taken. Photographs are not required  if the 
visit is not performed in -office.  
• Each  study area  will be  examined and  clinically assessed by the site investigator. If the visit 
is not performed in -office, clinical assessment is not required.  
• Any adverse events will be identified and documented. If the visit is not performed in office, 
the clinical site must  inquire regarding any adverse events either by phone call, text, e -mail 
or video conference.  
 
4.13 60-Day Post -Excision Follow -up Visit (Visit 9)  
• Photographic images of each study area will be taken .  
• Each  study area  will be clinically assessed by the site investigator.  
• The site investigator shall assess each treatment area based on the Manchester Scar Scale.  
• The site investigator shall complete the healing assessment questions  for each treatment 
area.  
• The subject sh all assess each treatment area based on the SCAR -Q Appearance Scale.  
• Any adverse events will be identified and documented.  
 
 
4.14  Subject Withdrawal  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 20 of 37  
A study subject has the right to discontinue participation at any time without penalty or loss of 
benefits to w hich the subject is otherwise entitles  or may be withdrawn at any time at the 
discretion of the investigator for safety, behavioral, compliance, or administrative reasons . A 
withdrawn subject will be treated according to standard of medical care and will n ot be replaced.  
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.  
If a participant withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the site study records.  
 
4.15 Discontinuation of  CellFX Treatment Session  
A participant may be discontinued from treatment with the CellFX System prior to completion of 
the entire treatment session  in the event of intolerable pain or system failure of the CellFX 
System.  If the study subject elects not to complete the treatment session, a study exit form shall 
be comp leted and documented as early termination. System failure of the CellFX System or 
component failure shall be documented on the Device Malfunction Form .  
 
4.16 Lost to Follow -Up 
A study subject will be considered lost to follow -up if he or she repeatedly fails t o return for 
scheduled visits and is unable to be contacted by the study site.  
 
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:  
• The site must attempt to contact the participant and reschedule t he missed visit as soon as 
possible , counsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain whether or not the participant wishes to and/or will continue in the 
study.  
• For  the surgical excision visit (Visit 6), the sites must confirm the surgical excision date with 
the participant 1 -2 times, 1 week to 1 day prior to the visit day  and reitera te the importance 
of completing the surgical excision visit in order to ensure the cancer does not return or 
spre ad. If the subject does not confirm and/or does not come in on their schedule excision 
date, the site must attempt to contact the participant with at least three phone calls. If the 
site cannot reach the participant, the site is to send a certified letter to the participant’s last 
known mailing address or local equivalent methods . 
• Before a participant is deemed lost to follow up, the investigator or designee must make 
every effort to regain contact with the participant (where possible, 3  telephone calls and , if 
necessary, a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact attempts are to be documented in the participant’s 
medical record.  
• If the participant continues to be unreachable, he/she will be  considered to have withdrawn 
from the study.  
5.0 BENEFITS AND RISKS  
5.1 Benefits  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 21 of 37  
There are no guaranteed benefits from participation in this study. Participation in the study 
offers another dermatological approach to accomplish the same clinical effect as the typical 
topicals, surgical devices or surgical excision currently used  to treat patients with BCC lesions . 
The information learned from this study may contribute to the ultimate use of a safer and more 
effectiv e device and the availability of the device to treat benign and non -benign lesions as an 
alternative for use in future patients.  
 
 
5.2 Risks  
For detailed information on the risks of the devices used in the study procedure, including a  
complete list of warning s, precautions , and potential adverse events, please refer to the 
Instructions for Use (IFU) for the Pulse Bioscience CellFX® System.  
An additional risk for study participants is the delay in performing surgical excision of the tumor; 
however, basal cell c arcinomas are slow -growing, so a dela y of 60 days is considered a minimal 
risk.  The wait times for standard surgical excisions are often longer than 60 days in some areas 
and practices. Because  biopsy and surgical excision are standard of care for basal cell carcinoma 
and will also be occurring in this study, risks of these procedures are not considered in the 
benefit/risk assessment.  
 
5.3 Mitigation of Risks  
As with any dermatological procedure, ap propriate safety precautions will be followed. Risks 
observed or theoretical adverse events have been mitigated through the Instructions for Use, 
physician training, and patient selection in the study protocol.  The subject will receive full care 
of their B CC lesion(s).  
All efforts will be made to minimize these risks by:  
• Site Selection  
• Patient Population that represents  the demographics of the U.S  
• Ensuring compliance to the protocol and IFU  
• Study monitoring  
• Safety processes -protocol adverse events reporting requirements  
 
The following plan is set in place in order to mitigate the risk of the study participant treated with 
the CellFX system not returning for their surgical excision visit to receive full care of their BCC 
lesion(s):  
• Prominent language is added to the Informed Consent Form to emphasize that the CellFX 
treatment has not yet been shown to remove all cells from a skin tumor, and therefore 
surgical removal is of the utmost importance to ensure that the cancer does not return or 
spread.  
• Training of the PI and their clinical study staff will emphasize the  importance of subject 
selection  in selecting subjects who will commit to all study visits, an explanation of the 
importance for all subjects to compl ete their surgical excision of the diagnosed BCC lesion, 
training to remind and confirm the study visits with the subjects at each visit, with emphasis 
on the surgical excision visit.  
• Subject compensation is structure d to motivate the subject to complete the surgical 
excision, and safety follow up visits with the highest compensation assigned to the surgical 
excision visit (Visit 6), higher monetary values assigned to the later follow -up visits (visits 7 -
9), as well as a n all-visit bonus offered for subjects who complete all study visits . 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 22 of 37  
• Site compensation includes an all -visit bonus to motivate the site to closely follow -up with 
the study subjects to ensure all visits are completed . 
• Remote and on -site monitoring of subje ct visits at all participating sites to ensure 
compliance of subject attending scheduled study visits.  
 
 
6.0 STATISTICAL CONSIDERATIONS  
  
6.1 General Approach  
For descriptive statistics, counts and percentages  will be calculated for categorical variables. 
Continuous variables will be summarized using the  mean , standard deviation , median, 
minimum and maximum.  No inferential tests are planned for this study, but 2 -sided confidence 
intervals will be produced where appropriate. Where 2 -sided p -values are calculated, they 
should be interpreted as descriptive only.  
 
6.2 Analysis of the Primary Effectiveness Endpoint  
The count and proportion with the primary endpoint of histological clearance will be calculat ed 
along with a 95% confidence interval  (CI). The primary population for this analysis will be the 
Per-Protocol population, though estimates will be produced for the modified intent -to-treat / 
safety population  (patients who begin treatment)  and Complete T reatment population 
(subjects who complete all required cycles of treatment).   
 
6.3 Analysis of Secondary Endpoints  
No formal hypothesis testing is planned for secondary endpoints. Any p -values comparing 
groups should be considered descriptive. The secondary e ndpoints will be evaluated using the 
modified intent -to-treat / safety  population, but these analyses may be repeated for  complete  
treatment and per-protocol populations as well.  
 
6.3.1 Change in Lesion Size  
Lesion size (as measured by the product of the longest perpendicular  diameters ) will  be 
calculated at baseline and at follow -up day  60 post -NPS treatment . The two longest 
diameters (longest length and  longest perpendicular  width) of each study lesion will be 
measured and the product will be calcul ated  for each individual study lesion at baseline 
and at 60 days -post NPS treatment study visits. Calipers will be provided to each study 
site to perform the measurements per standardized procedures. A standard adhesive 
ruler will also be included in photo graphs taken of each study lesion. Within -lesion 
change in lesion size from baseline to the 60 -Day follow -up time -point will be calculated. 
A mixed model for repeated measures will be used to estimate the mean reduction and 
its 95% confidence interval. Baseline lesion size will be included as a fixed effect.  
 
6.3.2 Lesion Reduction Category  
The visible/clinical clearance of the target lesions will be rated according to the lesion 
reduction categories listed in Table 4. The l esion reduction category will be derived from 
the lesion size measurements at baseline and follow -up day  60 Post -NPS treatment  
described in Section 6.3.1 . The % redu ction will be calculated as the change in lesion size 
divided by the baseline value. This percentage will be categorized according to the table  
4 below:  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 23 of 37  
 
 
 
 
Table 4. BCC Lesion Reduction Categories  
 
BCC Lesion Reduction Categories  
CLEAR  
0mm/100% reduction  MOSTLY CLEAR  
99-51% reduction  PARTIALLY CLEAR  
50-25% reduction  NOT CLEAR  
<25% reduction  
 
 
6.3.3 Partial response  of target (study) lesion  as assessed by WHO  criteria  
Partial response will be assessed using the WHO  criteria. Partial response is defined as a  
≥ 50% decrease in the product of  the perpendicular  diameter s of each  target /study BCC lesion 
compared to baseline.  The 50% reduction  will be determined through  the product  of the 
long est perpendicular bidimensional diameter s (longest length and longest perpendicular 
width) of each study lesion treated.  Calipers will be provided to each study site to perform 
the measurements per standa rdized procedures. A standard adhesive ruler will also be 
included in photographs taken of each study lesion. Partial response will be assessed for in -
clinic measurements at follow -up day  60 Post-NPS treatment . The number and proportion 
of lesions meeting the definition of partial response and confidence interval for the 
proportion will be calculated . 
 
6.3.4 SCAR -Q Appearance Scale (Subject)  
The SCAR -Q is a patient -reported outcome  instrument designed to  measure outcomes 
specific to any type of scar .  This instrument has subscales for scar appearance , psychosocial 
impact  and scar  symptoms . Least -square means and confidence intervals will be calculated 
for each scale and subscale using  generalized linear models with lesion size included as  a 
fixed effec t.  
 
6.3.5 Manchester Scar Scale (Investigator)  
The Manchester Scar Scale  evaluates the following five characteristics  of scar: color (score: 
1–4), distortion (score:  1–4), contour (score: 1 –4), texture (score:  1–4), and transparency 
(score: 1 –2). The distributi on of responses will be summarized for each characteristic. Least -
square means and confidence intervals will be calculated for the total score using generalized 
linear models with treatment lesion size included as  a fixed effect.  
 
 
6.3.6 Healing assessment ques tions (Investigator)  
The following assessment questions will be asked on the Day 60  post -NPS treatment  visit 
prior to surgical excision as well as  on the  Day 60 post -surgical excision  visit: 
a. Is the healing pattern cosmetically acceptable? (yes, no)  
b. How likely is a scar? (1 = unlikely, 2 = possible, 3 = probable)  
c. Once healed, how do you anticipate the treated area will look compared to curettage 
and desiccation? (1 = better, 2 = the same, 3 = worse)  
d. Once healed, how do you anticipate the treated  area will look compared to surgical 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 24 of 37  
excision? (1 = better, 2 = the same, 3 = worse)  
The distribution of responses will be summarized for each question.  
 
6.4 Safety Endpoints  
Unless otherwise noted, the safety population will be used to assess safety endpoints.  
6.4.1 Primary Safety Endpoint  
The primary safety endpoint is the incidence of any serious AEs or complications associated 
with the application of NPS (procedure and treatment). Information about AEs and 
complications will be solicited by site investig ators at scheduled follow -up visits.  The count 
and proportion with the primary  safety  endpoint  will be calculated along with a 95% 
confidence interval.  Adverse events and complications will also be summarized by MedDRA 
preferred term.  
 
6.4.2 Investigator Local Skin Reaction Assessment  
The Investigator  will perform  clinical assessments on the local skin reaction of the treatment 
area based on the following characteristics: presence and severity of erythema, edema, 
exudate, eschar, peeling scaling, bleeding,  ulceration, scarring,  and pigmentary changes. 
Assessment will be based on a validated 5 -point scale: None, Mild, Moderate, Moderate to 
Severe, Severe. The wound healing characteristics will be assessed by the investigator at the 
14-Day and 60-Days Post -NPS visits . The 3 -Day, 7-Day, and 30-Days Post -NPS visits are 
optional in -office and will be summarized separately and included as a descriptive analysis . 
The rate of each event individually and a composite of any of these events will be calculated 
for each treated lesion area.  The number and proportion of lesions with any reporting of any 
erythema, edema, exudate, eschar, peeling scaling, bleeding, ulceration, scarring,  or 
pigmentary changes (regardless of severity) will be summarized by time -point.   
 
6.4.3 Partic ipant Assessment of Procedural Pain  
The p articipant  will give an assessment of procedural pain on an 11 -point scale ranging from 
0 (no pain) to 10 (worst pain imaginable). The Pain Assessment Chart  with an assigned 
numerical rating between 0 (smiling) and 10 (crying) will be used to assess pain at Day 0, as 
reference in Figure 4. The pain scale will be asses sed immediately after each lesion treatment 
session .  
Pain levels will be grouped into four categories: No Pain (Score of 0), Mild Pain (Scores of 1 -
3), Moderate Pain (Scores of 4 -6) and Moderate -to-Severe Pain (Scores of 7 -10). The number 
and percent age will be tabulated for each category of pain, averaged for overall pain and 
may be analyzed against other parameters.  
 
 
   Figure 4: Pain Assessment Chart  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 25 of 37  
 
6.5 Sample Size Determination  
No formal hypothesis tests will be performed for this study, so the sample size was selected to 
produce a representative sample of BCC lesions to determine whether treatment effects are 
consistent  across study participants . A maximum of 30  participants will be treated to allow for 
assessment of the endpoints outlined in th is protocol.  
 
6.6 Populations for Analyses  
The following populations are defined in Table 5.  
 
Table 5. Population Descriptions for Analysis  
Population  Description  
Modified Intent -to-treat / 
Safety Population  All enrolled participants who began  treatment  with the CellFX system , 
irrespective of completed study treatment session, subsequent 
withdrawal, or deviation from the protocol .  
Complete Treatment  This population consists of m ITT participants who completed  the entire 
CellFX treatment session .  
Per-Protocol  Participants who received treatment, completed the CellFX treatment 
session, excision surgery and all required study visits . 
 
6.7 Sub-Group Analyses  
Subgroup analyses will be performed for the following subgroups:  
o Lesion Size Tertiles  
o Fitzpatrick skin type  
 
6.8 Interim Analyses  
No interim analysis is planned for this study.  
 
6.9 Missing Data  
All possible efforts will be made to minimize missing data in this study. However, based on 
previous studies, any missing data that does occur is likely due to missed follow -up visits. 
However, the sensitivity of the final results to missing data will be examined by comparing the 
primary outcomes to the results using  a longitudinal model with the 60 -day post treatment 
results, and a tipping -point analysis will be performed for the endpoints at 60 days to determine 
whether the missing data could change the inference compared to the primary models.  
6.10  Exploratory Analysis  

NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 26 of 37  
 Exploratory analysis may  be performed to compare the different BCC subtypes.  Wound healing 
characteristics for the post -excision area will also be assessed and compared to th e wound 
healing characteristics post -NPS.  
Exploratory analysis may be performed for d ermatologic similarities of skin type based on 
anatomic subcategories:  
▪ Sun-exposed limbs  
▪ Non -sun exposed limbs  
▪ Torso  
 
 
7.0 CLINICAL PHOTOGRAPHY  
  The Sponsor will use  standardized photographic capture methods  describ ed in the photography 
instruction manual . Photographs will be taken at each in-office study visit.  In order to ensure consistent 
serial clinical photography  is achieved during the study, all subject photographs will be reviewed 
(monitored) on an ongoing basis. Digital images will be transferred /stored  in a secure, password 
protected portal.  
 
 
8.0 ADVERSE EVENTS  
Pulse Biosciences will classify each reported Adverse Event according to ISO 14155:2011. All protocol 
specific AEs, whether device -related or not, will be recorded on the AE case report form  and reported . 
Data to be collected will include the description o f the AE, onset , and resolution dates (or whether the 
AE is ongoing), severity, management/treatment, outcome, and determination of the relationship to the 
device and/or procedure. All AEs related to the lesion site(s)  should be reported and classified by the site 
Investigator  and be followed by  the Investigator to determine the relationship of the AE to the device or 
the study procedure.   
All AE information will be collected from enrollment through  the last study visit at  60 days following the 
surgical excision of the BCC lesion(s) ( 120 Days after the  CellFX treatment session) . All AEs will be followed 
until the event has resolved (in the case of permanent impairment, the event will be followed until it 
stabilizes, and the ov erall clinical outcome has been ascertained). Medical occurrences that begin before 
receiving a CellFX treatment  but after obtaining informed consent will be recorded on the Medical 
History section of the CRF rather than the AE section.  
 
When reporting AEs /SAEs, the Investigator should include the following information:  
• Description of event  
• Onset of event  
• Duration of event (including resolution dates or whether the AE is ongoing)  
• Severity  
• Relationship to device  or procedure  
• Action taken  
• Subject  outcome  
 
Severity describes the intensity of an event and will be assessed as:  
• Mild : The AE does not interfere in a significant manner with the subject’s normal functioning 
level.  
• Moderate : The AE produces some impairment of function but not hazardous to health.  
• Severe : The AE produces significant impairment of function or incapacities and/or it is a hazard 
to the subject.  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 27 of 37  
 
Relationship to device or procedure will be assessed as:  
• Unlikely : There is no indication that the AE was caused by the investigational  or standard of 
care  device.  
• Possibly : It cannot be excluded that the AE was caused by the investigational  or standard of 
care  device.  
• Likely : A causal  relationship between the investigational  or standard of care  device and the AE 
is at least a reasonable possibility,  i.e. there is evidence or argument suggesting a causal 
relations hip.  
 
8.1 Adverse E vent Definitions  
8.1.1 Adverse Event (AE): ( ISO 14155:2011 3.2 )  
Any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory findings) in subjects, users , or other 
persons, whether or not related to the investigational medical device .  
NOTE 1: This definition includes events related to the investigational medical 
device .  
NOTE 2: This definition includes events related to the procedures involved.  
*For the p urposes of this protocol , only dermatologic AEs will be reported  to 
the Sponsor . 
 
8.1.2 Adverse Device Effect (ADE): ( ISO 14155:2011 3.1 )  
Adverse event related to the use of an investigational medical device  
NOTE 1: This definition includes adverse events resulting from insufficient or 
inadequate instructions for use, deployment, implantation, installation, or 
operation, or any malfunction of the investigational medical device.  
NOTE 2: This definition includes any event resulting from use error or from 
intentional misuse of the investigational medical device  
 
8.1.3 Serious Adverse Event (SAE) (ISO 14155:2011 3.37)  
 Adverse event that  
a) led to  death,  
b) led to serious deterioration in the health of the subject, that either resulted 
in  
1) a life -threatening illness or injury, or  
2) a permanent impairment of a body structure or a body function, or  
3) in -patient or prolonged hospitalization, o r  
4) medical or surgical intervention to prevent life -threatening illness or 
injury or permanent impairment to a body structure or a body function,  
 c) led to fetal distress, fetal death or a congenital abnormality or birth defect.  
NOTE 1: Planned hospitalization for a pre -existing condition, or a procedure 
required by the CIP, without serious deterioration in health, is not considered a 
serious adverse event.  
 
 
 
8.1.4 Serious Adverse Device Effect (SADE): (ISO 14155:2011 3.36)  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 28 of 37  
Adverse device effect that has resulted in any of the consequences characteristic 
of a Serious Adverse Event .  
 
8.1.5 Unanticipated Adverse Device Effect (UADE): (21CFR812.3)  
Any serious adverse effect on health or safety or any life -threatening problem 
or death caused by, or associated with, a device, if that effect, problem, or death 
was not previously identified in nature, severity, or degree of incidence in the 
investigatio nal plan or application, or any other unanticipated serious problem 
associated with a device that relates to the rights, safety, or welfare of subjects.  
 
8.2 Device Deficienc ies (ISO 14155:2011 3.15 )  
8.2.1 Definitions  
Device Deficiency  is an Inadequacy of a medical device with respect to its identity, 
quality, durability, reliability, safety , or performance .  
 
NOTE : Device deficiencies include malfunctions, use errors, and inadequate labelling.  
 
Device Malfunction  is a failure of the study device to perform in accordance with its   
intended purpose when used in accordance with the instructions for use or study 
protocol.  
 
8.3 Safety Reporting Requirements  
Table 6 summarizes the time sensitive requirements for adverse ev ents and device deficiencies.  
The Sponsor  is the contact person for these reporting requirements .  
 
                             Table 6. Investigator Responsibilities for Submitting Adverse Event s to the Sponsor  
Type of Adverse Event  Reporting Timeframe  
*Serious Adverse Device Effects 
(SADE), including Unanticipated 
Serious Adverse Device Effect 
(USADE)  As soon as possible, but in no case later than 3 calendar days 
after the clinical site first learns of the event or of new 
information in relation with an already reported event   
**Serious Adverse Events (SAE)  
 As soon as possible, but in no case later than 3 calendar days 
after the clinical site first learns of the event  or of new 
information in relation with an already reported event   
Adverse Device Effects (ADE)  
 As soon as possible, but in no case later tha n 3 calendar days 
after the clinical site study team first learns of the event  or of 
new information in relation with an already reported event  
All other AEs  
(dermatologic  only ) Submit in a timely manner after the clinical site first learns of 
the event   
**Device Deficiency with SADE 
potential  
 As soon as possible, but in no case later than 3 calendar days 
after the clinical site study team first learns of the deficiency 
or of new information in relation with an already reported 
deficiency  
All other D evice Deficiencies  
 Submit in a timely manner after the clinical site first learns of 
the deficiency  
 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 29 of 37  
*The Sponsor will report the results of an evaluation of an unanticipated serious or serious adverse 
device effect to the FDA and all reviewing IRBs and investigators within 10 working days after the 
Sponsor first received notice of the adverse effect per 21 CFR 812.150.  
 
**It is the responsibility of the investigator to inform their IRB of serious adverse events and device 
deficiencies as required by their IRB guidelines.  
 
 
9.0 STUDY MANAGEMENT  (SPONSOR RESPONSIBILITIES)  
9.1 Sponsor Ethical and Regulatory  Conside rations  
As the Sponsor of this clinical study, Pulse Biosciences has the overall responsibility for the 
conduct of the study, including assurance that the study meets US federal and local regulatory 
requirements appropriate to the conduct of the study and is conducted according to the 
Declaration of Helsinki, Protection of Human Volunteers (21 CFR 50), Institutional Review Boards 
(21 CFR 56), and Obligations of Clinical Investigators (21 CFR 312). The study sponsor will adhere 
to sponsor general duties as d escribed in ISO 14155:2011, Clinical investigation of medical 
devices for human subjects – Good clinical practice, and CFR Part 812, 50, 56, 54 and the World 
Medical Association Declaration of Helsinki.  
 
To maintain confidentiality, all evaluation forms, reports and other records will be identified by 
a unique subject  identification code (ID number). All study records will be kept in a locked , secure 
area and clinical information will not be released witho ut written permission of the subject, 
except as necessary for monitoring by the FDA. The Investigator must also comply with all 
applicable privacy regulations (e.g., Health Insurance Portability and Accountability Act of 1996).  
 
General Duties  
Pulse Biosci ences will ensure that the application is submitted to the appropriate regulatory 
authorities, obtaining copies of IRB approvals and ensuring documentation of IRB approvals prior 
to the shipping of devices, ensuring proper clinical site monitoring, ensurin g patient informed 
consent is obtained, providing quality data that satisfies regulations and informing the 
Investigators and IRBs of unanticipated adverse device effects, events, and deviations from the 
protocol as appropriate.  
 
9.2 Selection of Clinical Sites  
The primary requirements of site and Investigator selection and continued participation in the 
Trial include  adequate experience, commitment to safety, consistency in adherence to the 
protocol, and patient volume. The clinical site must have  facilities that are capable of processing 
patients in the manner prescribed by the protocol.  
 
The study sponsor, Pulse Biosciences, and its designees will select qualified Investigators, ship , 
or deliver devices only to participating Investigators, obtain  signed study agreements, and 
provide Investigators with the information necessary to conduct the study.  
 
9.3 Site Training  
The training of appropriate clinical site personnel will be the responsibility of the Sponsor. The 
Investigator is responsible for ensur ing that his/her staff conduct the study according to the 
protocol. To ensure proper device usage, uniform data collection, and protocol compliance, the 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 30 of 37  
Sponsor will present a formal training session to study site personnel which will review the 
Instructio ns for Use of the device, the Investigational Plan, instructions on data collection, 
schedules for follow -up with the study site coordinators, and regulatory requirements. Detailed 
feedback regarding completion of forms will be provided by the Sponsor  thro ugh the regular site 
monitoring . 
 
 
9.4 Investigator Training  
The Sponsor will provide appropriate Investigator training on the use of the CellFX  System, 
Handpiece, and Treatment Tips . Training will take place prior to the initiation of the clinical 
investigation. Training will address topics including indications for use of the device, 
management of complications, and instructions to subjects. Training will be documented for 
each physician on a training log, signed by both the physician and training representative . 
Photography training as well as training on the electronic data capture system and photo 
management system will also be conducted.  
 
 
9.5 Monitoring of Study Sites  
9.5.1 Monitoring Methods  
Monitoring functions for this study will be conducted by Pulse Biosciences. The study will 
be monitored to ensure that the protocol, applicable regulations, and Good Clinical 
Practice Guidelines are followed. The study monitor will ensure that the rights and well -
being of subjects are protected, and the clinical  trial data are accurate, complete, and 
verifiable.  Specific monitoring requirements are detailed in the study specific Monitoring 
Plan.  
Prior to subject enrollment, the Sponsor will obtain the essential regulatory documents 
required to initiate the study.  The Sponsor will be responsible for the review and 
approval of the following essential documents:  
 
• Current Protocol  Revision  
• Investigator  Agreement  
• IRB approval letter for the protocol and consent  form  
• IRB approved consent  form  
• IRB membership roster or assurance number  
Copies of file documents will be maintained by the  Sponsor.  
 
9.5.2 Periodic Monitoring Visits  (Onsite and Remote)  
Periodic monitoring visits will be made at the investigational site throughout enrollment 
of the clinical study to assure that the Investigator obligations are fulfilled, and all 
applicable regulations and guidelines are being followed. These visits will assure that the 
facilities are still acceptable; the protocol and investigational plan are being followed, 
the IRB/HREC has been  notified of approved protocol changes as required, complete 
records are being maintained, appropriate and timely reports have been made to the 
Sponsor and the IRB, device and device inventory are controlled and the Investigator is 
carrying out all agreed activities. The monitor will verify accuracy of CRF or EDC 
completion against source documents maintained at the site.  
 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 31 of 37  
During monitoring visits, the Monitor will perform a review of study eligibility, 
Inclusion/Exclusion criteria, informed consent, all re ports of device malfunction, all 
events meeting criteria for serious adverse event reporting as well as safety and efficacy 
endpoints.  
Additional review will be performed on a site -by-site basis, as warranted by the findings 
of previous monitoring visits.  
The monitor will ensure that Investigators are aware of the regulatory requirement to 
maintain information in the study subject’s medical records which corroborate data 
collected on the CRF or EDC system.  To comply with these regulatory requirements, the 
following information will be maintained and made available as required by the sponsor 
and/or regulatory inspectors:  
The monitor will compare key variables (demographics, inclusion/exclusion criteria, and 
safety) on the CRFs or EDC database with each subje ct’s source documents. Any 
discrepancies will be noted and resolved.  
 
9.5.3 Site Close -out Visit  
Upon completion of the clinical study (when all subjects enrolled have completed the 
follow -up visits and the CRFs or EDC and queries have been completed), the Sponsor will 
notify the site  of closeout  and a study  closeout  visit will be performed.  All CRFs,  unused  
study  devices,  and any unused study materials will be collected and returned to the 
Sponsor. The Monitor will ensure that the Investigat or’s regulatory files are up to date 
and complete and that any outstanding issues from previous visits have been resolved. 
Other issues which will be reviewed at this visit include discussing retention of study 
files, possibility of site audits, publicatio n policy, and notifying the IRB of study closure.  
 
9.6 Protocol Deviations  
A protocol deviation is defined as an event where the clinical Investigator or site personnel did 
not conduct the study according to the Investigational Plan or the Investigator Agreement.  
Deviations shall be reported to the Sponsor regardless of whether medically justifiable, pre - 
approved, or taken to protect the subject in an emergency. Subject specific deviations will be 
reported on the provided protocol deviation  form. Non -subject specific deviations will be 
reported to the sponsor in writing. Investigators will also adhere to procedures for reporting 
study deviations to their IRB in accordance with their specific IRB reporting policies and 
procedures.  
Good Clinic al Practice (GCP) regulations require that Investigators maintain accurate, complete , 
and current records, including documents showing the dates and reasons for each deviation from 
the protocol.  
 
9.7 Study Completion  
The study is considered completed after all  subjects have undergone all of their protocol required 
follow -up visits, all eCRFs have been submitted, all queries have been resolved, and all action 
items have been closed. All unused study materials and study devices will be collected and 
returned to P ulse Biosciences or appropriately discarded as per instruction. After study closure, 
a final report will be completed.  
 
9.8 Audits / Inspections  
Pulse Biosciences,  national/international regulatory authorities  and IRBs may conduct initiated 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 32 of 37  
audits or inspectio ns at the study sites during the course of, or after completion of the study.  
The Investigator shall allow access to the original medical records and provide all requested 
information.  
 
9.9 Publication Policies  
Publications based on the results of the study wi ll follow the process outlined in the Investigator 
Agreement.   The study will be registered on www.clinicaltrials.gov . 
 
9.10 Data Management  
Pulse Biosciences will be responsible fo r database creation and validation. Prior to finalizing and 
locking the database, all decisions concerning the inclusion or exclusion of data from the analysis 
for each subject will be determined by appropriate clinical and statistical personnel. All 
exclu sions related to either safety or efficacy will be documented in subject listings. Data  
management will follow department SOPs during the conduct of this feasibility study.  
 
9.11 Case Report Forms /Transmission of Data  
All required data for this study will be collected via web -based electronic data capture (EDC) 
system and entered in electronic Case Report Forms (eCRFs).  A unique study identifier will be 
assigned to each study subject. The database will contain only the  study identifier to identify the 
subject.  
Required data will be recorded on the appropriate electronic Case Report Forms at the time of 
or as soon as possible after the subject visit. This will enable timely monitoring visits.  
Any data discrepancies identified during data review or a monitoring visit will be queried by Pulse 
Biosciences and must be resolved by the site staff and Investigator in a timely manner.  
 
9.12 Data Retention  
Pulse Biosciences will maintain copies of correspondence, dat a, shipment of devices, adverse 
device effects, Investigator agreements and other records related to the clinical study. All study 
records and reports will remain on file at the sites for a minimum of 2 years after completion of 
the Study and will further be retained in accordance with local guidelines as identified in the 
clinical study agreement. Study records are to be discarded only upon notification by the study 
Sponsor. The Investigator must contact the study Sponsor before the destruction of any reco rds 
and reports pertaining to the study to ensure they no longer need to be retained. In addition, 
the Sponsor should be contacted if the Investigator plans to leave the investigational site. All 
required data for this study will be collected on standardiz ed CRFs or an electronic data capture 
system. All information and data sent to the Sponsor concerning subjects or their participation 
in this study will be considered confidential. All data used in the analysis and reporting of this 
evaluation will be used  in a manner without identifiable reference to the subject. The Principal 
Investigator consents to visits by the staff of the Sponsor and its authorized representatives and 
the U.S. Food and Drug Administration or any other local governmental body to revie w the study 
subjects’ medical records including any test or laboratory data that might have been recorded 
on diagnostic tests media (e.g., photographs, etc.).  
 
 
 
 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 33 of 37  
10.0 INVESTIGATOR RESPONSIBILITIES  
The role of the Principal Investigator is to implement and mana ge the conduct of the clinical study at 
their site, as well as ensure data integrity and the rights, safety , and well -being of the participating 
subjects.  
The Investigator shall ensure that all work and services described herein, or incidental to those 
described herein, shall be conducted in accordance with the highest standards of medical and clinical 
research practice. The Investigator will provide current copies of the study protocol to all Sub -
Investigators or other site personnel responsible for study conduct.  
Upon completion or termination of the study, the Investigator will submit a final written summary to 
the IRB. The summary should be submitted to the Sponsor within three (3) months of study completion 
or termination. The Investigator will provide the Sponsor with copies of all IRB/HREC actions regarding 
the study.  
 
10.1 IRB Approval and Informed Consent  
The clinical study must be reviewed and approved by the IRB before subject enrollment may 
begin. All proposed changes to the investigational plan must be reviewed and approved by Pulse 
Biosciences.  Prior to shipment of study devices, a signed copy of the IRB Committee approval 
letter identifying the clinical study must be submitted to Pulse Biosciences, signifying study 
approval . Investigators are responsible for obtaining and maintaining approval of the study by 
the IRB.  
Written informed consent is mandatory and must be obtained from all subjects prior to 
performing any study procedures in this clinical study. Pulse Biosciences will provide the site with 
a Sponsor approved consent template. Each site is expected to modify the template, if necessary, 
to meet their facilities requirements. Modified ICF templates must be reviewed by the Sponsor 
prior to submission to their IRB.  
Informed consent must be obtained and shall inform the subject as to the objective and 
procedures of the study and possible ri sks involved. The subjects must be informed about their 
right to withdraw from the study at any time and for any reason without sanction, penalty, or 
loss of benefits to which the subject is otherwise entitled and that withdrawal from the study 
will not jeopa rdize  their  future  medical  care.  The clinical  study  informed  consent  must  be used  in 
addition to any institutional standard consent form for participation in clinical research. The 
institutional standard subject consent form does not replace the study cons ent form.  
It is the responsibility of the investigator to obtain both an authorization for patient health 
information and study consent.  
The IRB approved Informed Consent Forms must be retained at the site along with the other 
investigational case report f orms  or source documents . A signed copy of the consent form must 
be given to each subject enrolled in the study.  
 
10.2 Data Collection and Reporting  
Case report forms  or source documents  will be used to record demographic, procedural, and 
follow -up data, as wel l as any adverse events which may occur during the study period. The AEs 
and incidence of morbidity and mortality will be reviewed with Investigators to assess the safety 
of the device and the procedure.  
The Investigator must comply with the safety reporting requirements specified in Section 8.3. 
Qualified study staff at each clinical site will perform primary data collection drawn from source - 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 34 of 37  
document (hospital  or clinic  chart) reviews. The Monitor will perform clinical monitoring, 
including review of CRFs , source documents and/or Electronic Data Capture ( EDC) system  with 
verification of study eligibility, informed consent process, scheduled follow -up visits and AEs to 
the source documentation.  
 
10.3 Source Do cuments  / Records Retention  
The investigator shall maintain accurate, complete, and current records relating to the 
investigator's participation in an investigation including records of each subject's case history 
and exposure to the device. Case histories  include the case report forms and supporting data 
including, for example, signed and dated consent forms and medical records including, progress 
notes of the physician, the individual's hospital or clinic chart(s), and the nurses' notes. Such 
records shal l include:  
 
1. Documents evidencing informed consent and, for any use of a device by the investigator 
without informed consent, any written concurrence of a licensed physician and a brief 
description of the circumstances justifying the failure to obtain informed consent. The case  
history  for each  subject  shall  document  that informed  consent  was obtained  prior to participation 
in the  study.  
 
2. All relevant observations, including records concerning adverse device effects (whether 
anticipated or unanticipated), information and data on the condition of each subject upon 
entering,  and during  the investigation,  including  information  about  relevant previous  medical  
history  and the results  of all diagnostic  tests.  
 
Investigator files containing all rec ords and reports of the investigation should be retained for a 
minimum of 5 years after the completion or termination of the investigational study or until two 
years after they are no longer needed to support product approval. They may be discarded upon 
notification by Pulse Biosciences. To avoid any error, the Investigator should contact Pulse 
Biosciences before destroying any records and reports pertaining to the study to ensure they no 
longer need to be retained.  
 
10.4 Device Accountability  
The Investigator s hall maintain adequate records of the receipt and disposition of all study 
devices. When the enrollment is complete, the Investigator shall return any unused devices to 
the Sponsor . At the completion of the study, all devices shall be returned to the Sponsor . The 
Investigator’s copy of the Device Accountability Log must document devices that have been 
returned to the sponsor.  
 
The device accountability log will include records of receipt, use or disposition of a device that 
relate to:  
 
1. The type  and quantity  of the device,  the dates  of its receipt,  and the lot number.  
2. The names  of all persons  who  received,  used,  or disposed  of each  device.  
3. Why and how many device (s) were  returned to the Sponsor , or otherwise disposed  of. 
  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 35 of 37  
 
11.0 REFERENCES  
1. Lomas A, Leonardi -Bee J, Bath -Hextall F. A systematic review of worldwide incidence of 
nonmelanoma skin cancer. Br J Dermatol. 2012;166(5):1069 -1080.  
2. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Basal cell 
skin cancer version 1. 2018.  
3. Migden MR, Chen L, Silapunt S, eds. Basal cell carcinoma. Advances in treatment and 
research. Switzerland: Springer Nature Switzerland AG, 2020.  
4. Oldfield, V., Keating, G.M. & Perry, C.M. Am J Clin Dermatol (2005) 6: 195. 
https://doi.org/10.2165/00128 071-200506030 -00006  
5. Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, Owens M. Imiquimod 5% cream for 
the treatment of superficial basal cell carcinoma: a double -blind, randomized, vehicle -
controlled study. J Am Acad Dermatol. 2002 Sep;47(3):390 -8. doi: 
10.1067/mjd.2002.126215. PMID: 12196749.  
6. Van der Geer S, Martens J, van Roij J, Brand E, Ostertag JU, Verhaegh ME, Neumann HA, 
Krekels GA. Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular 
basal cell carcinoma in the face: a  prospective randomized controlled study. Br J Dermatol. 
2012 Jul;167(1):110 -5. doi: 10.1111/j.1365 -2133.2012.10924.x. Epub 2012 May 21. PMID: 
22385074.  
7. Bahner JD, Bordeaux JS. Non -melanoma skin cancers: photodynamic therapy, cryotherapy, 
5-fluorouracil, i miquimod, diclofenac, or what? Facts and controversies. Clin Dermatol. 2013 
Nov-Dec;31(6):792 -8. doi: 10.1016/j.clindermatol.2013.08.020. PMID: 24160289.  
8. R. Cornell, et all. Intralesional interferon therapy for basal cell Carcinoma. AAD VOLUME 23, 
ISSUE 4 , P694 -700,  OCTOBER 01, 1990  
9. Cho M, Gordon L, Rembielak A , Woo TC. Utility of radiotherapy for treatment of basal cell 
carcinoma: a review. Br J Dermatol. 2014 Nov;171(5):968 -73. doi: 10.1111/bjd.13253. Epub 
2014 Oct 26. PMID: 25041560  
10. Megna M, Fabbrocini G, Marasca C, Monfrecola G. Photodynamic Therapy and Skin  
Appendage Disorders: A Review. Skin Appendage Disord. 2017;2(3 -4):166 -176.  
11. Shah, Sonali M, Konnikov, Nellie, Duncan,  Lyn M., Tannous, Zeina S. The effect of 595 nm 
pulsed dye laser on superficial and nodular basal cell carcinomas. 08 July 2009. 
https://doi.org/10.1002/lsm.20787  
12. Klassen AF, Ziolkowski N, Mundy LR, Miller HC, McIlvride A, DiLaura A, Fish J, Pusic AL. 
Development of a New Patient -reported Outcome Instrument to Evaluate Treatments for 
Scars: The SCAR -Q. Plast Reconstr Surg Glob Open. 2018 Apr 24;6(4):e1672. doi: 
10.1097/GOX.0000000000001672. PMID: 2987 6160; PMCID: PMC5977950 . 
13. Fearmonti R, Bond J, Erdmann D, Levinson H. A review of scar scales and scar measuring 
devices.  Eplasty. 2010;10:e43. 2010 Jun 21.  
 
12.0 APPEND ICES   
12.1 Appendix A: Patient Informed Consent  
12.2 Appendix B: Case Report Forms   
  
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 36 of 37  
APPENDIX A: Patient Informed Consent  
 
Patient Informed Consent will be provided as a separate attachment . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NP-TR-014 – CellFX T reat & Resect  BCC Feasibility Study                     
   
Page 37 of 37  
 
APPENDIX B: Case Report Forms  
 
Case Report Forms will be provided as a separate attachment . 
 